medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 6

<< Back Next >>

Ann Hepatol 2016; 15 (6)

Treatment of chronic HBV infection in developing countries

Zampino R, Sagnelli C, Boemio A, Sagnelli E, Coppola N

Language: English
References: 94
Page: 816-823
PDF size: 159.58 Kb.


ABSTRACT

Due to virological, host and socio-economic factors, the clinical presentation and treatment of chronic hepatitis B (CHB) differs between developing and developed countries and may differ between one low-income country and another. National healthcare prevention and treatment policies, environmental factors, social habits and personal life-styles all influence HBV transmission and the clinical management and therapy of CHB. These factors can have a strong impact on the natural history of the disease and on access to treatment and may eventually determine substantial changes in disease progression and the development of serious complications and hepatocellular carcinoma. In this review article, we analyze the clinical characteristics and access to antiviral treatment of CHB patients in low-income countries in Africa, Asia, Eastern Europe and Latin America.


REFERENCES

  1. Available from: http://www.who.int/mediacentre/factsheets/ fs204/en/

  2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 14: 582-92.

  3. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.

  4. Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.

  5. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55.

  6. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011; 55: 183-91.

  7. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-10.

  8. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-34.

  9. Iloeje UH, Yang HI, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.

  10. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.

  11. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65-S70.

  12. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-9.

  13. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.

  14. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011; 16: 1169-86.

  15. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis 2011; 31: 115-27.

  16. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61(Suppl. 1): 16-17.

  17. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613-6.

  18. Mast EE, Ward JW. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, Offit PA (Eds.). Vaccines. 5th Ed. Philadelphia, PA: Saunders; 2008.

  19. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181.

  20. McMahon BJ, Holck P, Bulkow L, Snowball MM. Serologic and clinical outcomes 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.

  21. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82.

  22. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58.

  23. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. New Engl J Med 2002; 347: 168-74.

  24. Harris RA, Chen G, Lin WY, Shen FM, London WT, Evans AA. Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control 2003; 14: 995-1000.

  25. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.

  26. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.

  27. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-72.

  28. Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int 2014; 34(Suppl. 1): 139-45.

  29. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.

  30. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98.

  31. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-7.

  32. Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21: 1769-71.

  33. Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, et al. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol 2012; 84: 217-22.

  34. Yang J, Chen X, Zhang H, Chen G. HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma. J Med Virol 2014; 86: 913-7.

  35. Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19: 3861-65.

  36. Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. PLoS One 2012; 7: e32789.

  37. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.

  38. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to ontreatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53: 118-25.

  39. Lampertico P,Vigano’ M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative. Patients developing genotypic resistance to Lamivudine. Hepatology 2005; 42: 1414-9.

  40. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.

  41. Chang TT, Lai CL, Kew Yoon SK, Lee SS, Coelho S, Carrilho FH, Poordad F, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.

  42. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.

  43. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-42.

  44. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014; 147: 152-61.

  45. Ive P, MacLeod W, Mkumla N, Orrell C, Jentsch U, Wallisa CL, Stevens W, et al. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One 2013; 8: e74900.

  46. World Health Organization (WHO). 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://www.who.int/hiv/ pub/guidelines/arv2013/en/index. html.

  47. Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, et al. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS 2014; 28(Suppl. 1): 35-46.

  48. Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, et al. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 2013; 27: 919-27.

  49. Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, Scott J, et al. PLoS One 2013; 8: e59346.

  50. Hamers RL, Zaaijer HL, Wallis CL, Siweale M, Ive P, Botes ME, Sigaloff KC, et al. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr 2013; 64: 174-82.

  51. Chadwick D, Ankcorn M, Sarfo F, Phillips R, Fox Z, Garcia A, Appiah L, et al. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother 2012; 67: 2939-42.

  52. Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 2012; 17: 321-6.

  53. Aoudjane S, Chaponda M, González Del Castillo AA, O’Connor J, O’Connor J, Noguera M, Beloukas A, et al. Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Re sistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi. Clin Infect Dis 2014; 59: 1618-26.

  54. Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat 2013; 20(Suppl. 2): 1-20.

  55. Ola SO, Anomneze EE, Chukwuani CM, Ojo OS, Ndububa DA, Onyenekwe B, Nasidi A. Interferon alfa-2a (Roferon-A) in the management of chronic hepatitis B infection: results of an open prospective study in Nigerian patients. West Afr J Med 2000; 19: 259-64.

  56. Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. J Infect 2014; 69: 81-7.

  57. Tan TW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, et al. Natural YMDD motif mutants affect clinical course of lamivudine in chronic hepatitis B. World J Gastroenterol 2015; 21: 2089-95.

  58. Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P, Ren H. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a metaanalysis. Virol J 2014; 11: 59.

  59. Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs. entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19: 6278-83.

  60. Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, et al. Respons-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study. World J Gastroenterol 2015; 21: 653-60.

  61. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, et al. The 104-week efficacy and safety of telbivudine-besed optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 2014; 59: 1283-92.

  62. Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat 2013; 20(Suppl. 1): 40-5.

  63. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007; 60: 201-5.

  64. Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013; 20: 811-20.

  65. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatmentnaive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-71.

  66. Hou J, Jia J, Wei L. Entecavir versus other standard of care for up to 4 years in nucleos(t)ide-naive patients with CHB in Chinese clinical practice. Abstract presented at the Third Asian Pacific Association for Study of the Liver, June 6–10, 2013, Singapore.

  67. Lu L, Yip B, Trinh H, Pan CQ, Han SH, Wong CC, Li J, et al. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat 2015; 22: 675-81.

  68. Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014; 39: 629-37.

  69. Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, et al. Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/mL). Liver Int 2015; 35: 422-8.

  70. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014; 146: 1240-8.

  71. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.

  72. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-47.

  73. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014; 147: 152-61.

  74. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57: 2423-9.

  75. Celen MK, Mert D, Ay M, Kaya S, Yildirim N, Gulsun S, Barcin T, et al. The efficacy and safety of tenofovir disoproxil in pregnancy for the prevention of vertical transmission of HBV infection. 23th Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int Berlin 2013; 7(Suppl. 1): 216.

  76. Greenup AJ, TanPK, Lawlor J, Glass A, Chatterjee U, Davison S, Smith L, et al. Tenofovir use in pregnant women with chronic Hepatitis B: virological efficacy and mother and child safety. 23th Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int Berlin 2013; 7 (Suppl. 1): S266.

  77. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, Hu JJ, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015; 62: 375-86.

  78. Hu YH, Liu M, Yi W, Cao YJ, Cai HD. Tenofovir rescue therapy in pregnant females with chronic hepatitis B. World J Gastroenterol 2015; 21: 2504-9.

  79. Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013; 20(Suppl. 1): 65-70.

  80. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31.

  81. Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 59: 709-16.

  82. Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, et al. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014; 21: 662-70.

  83. Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, et al. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2014; 19: 245-57.

  84. Juszczyk J, Boroñ-Kaczmarska A, Cianciara J, Flisiak R, Gladysz A, Halota W, Kryczka W, et al. Therapeutic recommendations for 2013: antiviral treatment for chronic hepatitis B. Przegl Epidemiol 2013; 67: 287-95, 383-91.

  85. Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, et al. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients. J Gastrointestin Liver Dis 2009; 18: 425-31.

  86. Gheorghiþa VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Colþan G, Streinu-Cercel A. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. J Gastrointestin Liver Dis 2013; 22: 27-32.

  87. Preda CM, Baicus C, Negreanu L, Tugui L, Olariu SV, Andrei A, Zambatu I, et al. Effectiveness of entecavir treatment and predictive factors for virologic response. Rev Esp Enferm Dig 2014; 106: 305-11.

  88. Milosevic I, Delic D, Lazarevic I, Pavlovic IP, Korac M, Bojovic K, Jevtovic D. The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia. J Clin Virol 2013; 58: 54-8.

  89. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-8.

  90. Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, et al. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. Antivir Ther 2014; 19: 235-43.

  91. Mata-Marín JA, Mata-Marín LA, Arroyo-Anduiza CI, Huerta- García G, Sandoval-Ramírez JL, Manjarrez-Tellez B, Gaytán- Martínez JE. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabinecontaining regimen. Hepatogastroenterology 2014; 61: 1187-91.

  92. Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008; 22: 1779-87.

  93. Alvarado-Esquivel C, De la Ascensión Carrera-Gracia M, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, Aguilar- Benavides S, Torres-Valenzuela A, et al. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother 2006; 57: 221-3.

  94. Mello FC, Fernandes CA, Gomes Sde A. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz 2012; 107: 317-25.




2020     |     www.medigraphic.com